Storing antibodies at various temperatures (up to 40°C) for one week does not affect their activity. As a precautionary measure, we ship all products in insulated packaging with cold packs to provide extra temperature stability in transit. The cold packs may be thawed when you receive the shipment, please be assured that this is normal and your product(s) are safe to use. Once you have received your product(s), please follow the storage instructions on the datasheet(s).
*USAGE / SAFETY STATEMENT
This product is for research use only. It is not intended for diagnostic or therapeutic use.
APPLICATION
FC, IF
CONCENTRATION
200 µg/ml
PHYSICAL FORM
Liquid
SUBCLASS
Monoclonal
CLONE NUMBER
CG106
HOST SPECIES
Mouse
ISOTYPE
IgG2a
REACTIVITY SPECIES
Human
CLONALITY
Monoclonal
PURIFICATION
Protein A/G chromatography.
IMMUNOGEN
Stimulated human leukocytes.
STORAGE BUFFER
Supplied in 10mM Phosphate Buffered Saline with 0.05% BSA and 0.05% Sodium Azide.
CONJUGATION/TAG
Unconjugated
SPECIFICITY
Recognizes the D1 domain of an N-glycosylated glycoprotein of 120kDa with intra-chain disulfide bonds, identified as CD50 or ICAM-3 (Leucocyte Workshop VI). CD50 is the major ligand for LFA-1 (CD11a/CD18) and may have signaling role to increase adhesion. It is expressed on thymocytes and T lymphocytes and is resistant to treatment with phosphatidylinositol (PI) phospholipase C. This MAb is excellent for staining of formalin/paraffin tissues.
DILUTION
FC: 1-2 µg / million cells, IF: 1-2 µg/ml
TARGET ORGANS
ICAM3
GENERAL NOTES
This antibody blocks binding of CD11a to ICAM-3; order antibody without Sodium Azide!
LIGHT CHAIN
kappa
Questions & Answers (0)
Citations (0)
Shipping & Handling
Shipped In
Cold Packs
Safety & Storage
Storage Temperature
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Safety Statement
This product is for research use only. It is not intended for diagnostic or therapeutic use.
Regulatory & Compliance
We’re currently in BETA - Interested in joining? Let us know and we’ll get you set up with early access.